Απ: Eξαιρετική συνέντευξη του CEO της Replicel
"EQ: The company’s first-in-man, Phase I/IIa clinical trial was started in December 2010, and the last patient was injected in August 2011. What’s next for RepliCel in this trial, and what are you hoping to see in the results?
Hoffmann: Phase I trials are about safety, so a successful trial is, of course, about safety. Most people on the outside are not interested in safety; they’re interested in hair growth. For the regulators, the first thing we must prove is that it’s safe. A successful trial will prove that it’s completely safe, with no adverse effects like ganuloma or tumor formations. A very successful trial would mean we see more hair growth at the levels we would expect to see in a patient treated with Rogaine®. So, a range of 10 percent to 15 percent more hairs per centimeter square is what we would define as very successful. If we see even more hairs than what is expected from finasteride (Propecia®) treatments, then we’d be very, very happy. So first of all, it’s a safety treatment. But secondary, we are also looking for hair density and more parameters linked to efficacy."
Οπότε οι ενέσεις έγιναν με μικρές ποσότητες ίσα ίσα να δουν εαν είναι ασφαλές.
Παιδιά, αν όντως βγει στην πράξη τόσο αποδοτικό όσο φαίνεται στη θεωρία, τότε δε ξαναπαίρνουμε κανένα "φάρμακο"!
Είμαι περίεργος πάντως να δω έστω και φωτογραφία του 1ου ασθενή από το Δεκέμβρη το 2010!!!
Αν τελικά πάρει το δρόμο της μαζικής εφαρμογής, θα πρέπει να είναι σε 5 χρόνια minimum. Λένε για 2015, αλλά τα συμφέροντα για τις πατέντες και την εφαρμογή θα το καθυστερήσουν λίγο θεωρώ.
